NCT02157103View on ClinicalTrials.gov

A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

January 31, 2018

Conditions
Glioblastoma
Interventions
DRUG

Bevacizumab 25 mg in 1 ml subcutaneously daily

Bevacizumab delivered by subcutaneous injection instead of intravenous infusion.

Trial Locations (2)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Winship Cancer Institutute, Atlanta

All Listed Sponsors
lead

Emory University

OTHER

NCT02157103 - A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma | Biotech Hunter | Biotech Hunter